StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report issued on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Performance
NASDAQ:EVOK opened at $0.56 on Friday. The stock has a market capitalization of $4.82 million, a PE ratio of -0.31 and a beta of 0.36. Evoke Pharma has a fifty-two week low of $0.40 and a fifty-two week high of $1.77. The company has a fifty day moving average of $0.49 and a two-hundred day moving average of $0.67.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share for the quarter. The company had revenue of $1.74 million for the quarter. Evoke Pharma had a negative return on equity of 4,908.09% and a negative net margin of 116.75%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Articles
- Five stocks we like better than Evoke Pharma
- Investing in large cap stocks: Diving into big caps
- The Top 3 Sectors Poised For Growth This Summer
- How to Read Stock Charts for Beginners
- U.S. Steel Stock: Betting on EPS Cut and Merger Uncertainty?
- Consumer Discretionary Stocks Explained
- GitLab Stock: Pioneering the AI-Powered DevSecOps Platform
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
